DANBURY, Conn., Sept. 1 /PRNewswire-FirstCall/ -- Biodel Inc. (Nasdaq: BIOD) announced today that Linjeta (pronounced lin-JET-uh) will replace VIAject as the proposed trade name for Biodel’s most advanced product candidate. The change follows FDA’s review and acceptance of Linjeta as an alternative name for Biodel’s more-rapid-acting insulin formulation that is currently under review by the U.S. Food and Drug Administration with a Prescription Drug User Fee Application date of October 30, 2010.
Dr. Errol De Souza, Biodel ‘s president and chief executive officer, stated: “Today’s news reflects the continued progress of the Linjeta new drug application through FDA review and is an important milestone in our effort to commercialize this new drug candidate.”
About Biodel Inc.
Biodel Inc. is a specialty biopharmaceutical company focused on the development and commercialization of innovative treatments for diabetes. Biodel’s product candidates are developed using VIAdel technology, which reformulates existing FDA-approved peptide drugs. Biodel’s new drug application for Linjeta, its most advanced product candidate, has been accepted for review by the FDA with a Prescription Drug User Fee Act action date of October 30, 2010. Earlier-stage product candidates include VIAtab, a sublingual tablet formulation of insulin, a line of basal insulins and a stabilized formulation of glucagon. For further information regarding Biodel, please visit the company’s website at www.biodel.com.
Contact: | |
The Trout Group LLC | |
Seth D. Lewis, +1-646-378-2952 | |
SOURCE Biodel Inc.
